Agents and compositions for the treatment of glioblastoma
AssigneeUniversity of Cincinnati
InventorsDavid Plas, Kelli Ennis
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions including a combination of therapeutic agents comprising a therapeutically effective amount of merestinib and a therapeutically effective amount of LY2584702. Also provided herein are methods of treating glioblastomas in a subject by administering the disclosed compositions, as well as methods of inducing cell death in a PTEN-deficient glioblastoma cell by administering the disclosed compositions.
Claims19
A pharmaceutical composition comprising:
- a therapeutically effective amount of merestinib;
- a therapeutically effective amount of LY2584702;
- and
- one or more pharmaceutically acceptable excipients.
A method of inducing cell death in a phosphate and tensin homolog (PTEN)-deficient glioblastoma cell, the method comprising administering to the cell a combination of therapeutic agents comprising:
- a therapeutically effective amount of merestinib;
- and
- a therapeutically effective amount of LY2584702,
- wherein cell death of the PTEN-deficient glioblastoma cell is induced.
A method of treating PTEN-deficient glioblastoma in a subject in need thereof, the method comprising administering to the subject a combination of therapeutic agents comprising:
- a therapeutically effective amount of merestinib;
- and
- a therapeutically effective amount of LY2584702.
Dependencies are inferred from the claim text.